MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...
(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...
In one particular study involving three patients with leg ulcers, Dooms-Goossens and Degreef discovered that the patients reacted to petrolatums on their leg ulcers despite having negative patch ...
This bitesize learning video explores: • Red flags that should be considered when a patient presents with a lower limb wound • When to escalate concerns • Immediate ‘first aid’ for lower limb wounds ...
The Department’s action is particularly good news for Medicare beneficiaries suffering from diabetic foot ulcers and venous leg ulcers. These patients will be able to access needed treatments in ...
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...
MediWound (MDWD) stock rises 4% as it begins Phase 3 trials for EscharEx treating venous leg ulcers, with FDA submission plans and mid-2026 interim ...
MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback